P
US7592329B2ExpiredUtilityPatentIndex 79

Crystalline complexes of fluticasone-2-furoate

Assignee: GLAXO GROUP LTDPriority: Feb 4, 2002Filed: Feb 4, 2003Granted: Sep 22, 2009
Est. expiryFeb 4, 2022(expired)· nominal 20-yr term from priority
Inventors:BIGGADIKE KEITHCOOTE STEVEN JOHNCRAIG ANDREWCROWE DAVID MALCOLMJACEWICZ VICTOR WITOLDMILLAN MICHAEL JOHNNICE ROSALYN KAYNOGA BRIANSEAGER JOHN FREDERICKTHEOPHILUS ANDREW LEWIS
A61P 5/44A61P 37/08A61P 29/00C07J 31/00C07J 17/00
79
PatentIndex Score
10
Cited by
215
References
10
Claims

Abstract

There is provided a crystalline complex comprising a compound of formula (I) in which the crystal lattice is stabilized by the presence of a guest molecule, characterized in that the crystalline complex is of space group P212121 having unit cell dimensions of about 12.5±1.0 §, 15±1.0 §, and 16.2±1.0 § when determined at either 120K or 150K.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. A crystalline complex comprising a compound of formula (I) 
       
         
           
           
               
               
           
         
       
       in which the crystal lattice is stabilised by the presence of a guest molecule, characterised in that the crystalline complex is of space group P2 1 2 1 2 1  having unit cell dimensions of about 12.5±1.0 Å, 15±1.0 Å, and 16.2±1.0 Å when determined at either 120K or 150K, wherein the guest molecule comprises one or more of t-butylamine, cyclohexanone, pyridine, butylamine, cyclohexylamine, or ε-caprolactam. 
     
     
       2. A complex according to  claim 1  wherein the guest molecule is liquid at ambient temperature and pressure. 
     
     
       3. A complex according to  claim 1  wherein the guest molecule is ε-caprolactam. 
     
     
       4. A complex according to  claim 1  wherein the guest molecule is selected from the group consisting of t-butylamine and cyclohexylamine. 
     
     
       5. A complex according to  claim 1  wherein the guest molecule is cyclohexanone. 
     
     
       6. A complex according to  claim 1  wherein the guest molecule is pyridine. 
     
     
       7. A complex according to  claim 1  wherein the guest molecule is t-butylamine. 
     
     
       8. A complex according to  claim 1  wherein the guest molecule is cyclohexylamine. 
     
     
       9. A complex according to  claim 1  wherein the molar ratio of compound of formula (I) to guest molecule is 1:2.0 to 1:0.3. 
     
     
       10. A pharmaceutical composition comprising a complex according to  claim 1  together with a physiologically acceptable diluent or carrier.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.